Skip to main content
SpringerLink
Log in

HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction

This study was to investigate whether the expression of a disintegrin and metalloproteinase-9 (ADAM9) is correlated with the expression of hepatoma-derived growth factor (HDGF) in surgically resected non-small cell lung cancer (NSCLC), to evaluate the significance of HDGF and ADAM9 as novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for postoperative adjuvant chemotherapy in surgically resected stage I NSCLC, to provide essential consistence proof to the possible novel pathway of HDGF–ADAM9 pathway.

Methods

Sixty-three cases of resected stage I NSCLC with mediastinal N2 lymph node dissection were immunohistochemically analyzed for HDGF and ADAM9 protein expression. Multivariate analysis and survival analysis were conducted.

Results

HDGF and ADAM9 were observed highly expressed in NSCLC compared with normal control lung tissues (P < 0.05). HDGF high expression cases showed significantly lower survival rate (55.6 vs. 84.7 %, P = 0.009). HDGF high expression was an independent factor of shortened survival time in resected stage I NSCLC (P = 0.015). ADAM9 high expression cases showed significantly lower survival rate (56.9 vs. 88.7 %, P = 0.015). ADAM9 high expression was an independent factor of shortened survival time in resected stage I NSCLC (P = 0.021). Pearson’s correlation analysis revealed that ADAM9 expression was correlated positively and significantly with HDGF expression in 63 cases of stage I NSCLC (r = 0.547, P = 0.000).

Conclusion

These results clearly demonstrate that ADAM9 high expression is correlated positively and significantly with HDGF high expression, which provides essential evidence for the novel HDGF–ADAM9 pathway, through which HDGF promotes invasion and metastasis of NSCLC cells; HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers, which might become useful predictive biomarkers for the selection of postoperative adjuvant chemotherapy treatment in surgically resected stage I NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Besse B, Chevalier TL (2008) Adjuvant chemotherapy for non–small-cell lung cancer: a fading effect? JCO 26:5014–5017

    Article  Google Scholar 

  • Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C (2005) The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 26:17–24

    CAS  PubMed  Google Scholar 

  • Douillard JY, Gauducheau CR (2010) Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. JCO 28(1):3–5

    Article  CAS  Google Scholar 

  • Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA (2000) Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 105:567–575

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A (2004) Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 286:L1194–L1201

    Article  CAS  PubMed  Google Scholar 

  • Fritzsche FR, Jung M, Tölle A et al (2008a) ADAM9 Expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 54:1097–1106

    Article  CAS  PubMed  Google Scholar 

  • Fritzsche FR, Wassermann K, Jung M et al (2008b) ADAM9 is highly expression in renal cell cancer and is associated with tumour progression. BMC Cancer 8:179

    Article  PubMed Central  PubMed  Google Scholar 

  • Grutzmann R, Luttges J, Sipos B et al (2004) ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 90:1053–1058

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Iwasaki T, Nakaqawa K, Nakamura H, Takada Y, Matsui K, Kawahara K (2005) Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep 13:1075–1080

    CAS  PubMed  Google Scholar 

  • Liu Q, Zhang J (2013) Abnormal expression of GLO1 in non-small cell lung cancer. Zhongguo Yike Daxue Xuebao 42:77–78 (In Chinese)

    CAS  Google Scholar 

  • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594

    Article  PubMed Central  PubMed  Google Scholar 

  • Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717

    Article  CAS  PubMed  Google Scholar 

  • Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF (1995) Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 60:466–472

    Article  CAS  PubMed  Google Scholar 

  • O’Shea C, Mckie N, Buggy Y et al (2003) Expression of ADAM9m RNA and protein in human breast cancer. Int J Cancer 105:754–761

    Article  PubMed  Google Scholar 

  • Ren H, Tang X, Lee JJ et al (2004) Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. JCO 22:3230–3237

    Article  CAS  Google Scholar 

  • Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

    Article  PubMed  Google Scholar 

  • Tannapfel A, Anhalt K, Hausermann P et al (2003) Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol 201:238–249

    Article  CAS  PubMed  Google Scholar 

  • Uyama H, Tomita Y, Nakamura H et al (2006) Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12:6043–6048

    Article  CAS  PubMed  Google Scholar 

  • Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M (2001) Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37:2264–2274

    Article  CAS  PubMed  Google Scholar 

  • Xie Y, Minna JD (2010) Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy. JCO 28:4404–4407

    Article  CAS  Google Scholar 

  • Yamamoto S, Tomita Y, Hoshida Y et al (2006) Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12:117–122

    Article  CAS  PubMed  Google Scholar 

  • Yamamoto S, Tomita Y, Hoshida Y et al (2007) Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 14:2141–2149

    Article  PubMed  Google Scholar 

  • Zhang J, Mao L (2006) SiRNA targeting hepatoma-derived growth factor (HDGF) inhibits growth of non-small cell lung cancer in xenograft models. Tumor Biology 35: Emerging Molecules, Mechanisms, and Models. Proc Amer Assoc Cancer Res 47:abstract #5135

  • Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L (2006) Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66:18–23

    Article  CAS  PubMed  Google Scholar 

  • Zhang J, Qi J, Guo Y et al (2011a) Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14:211–218 (In Chinese)

    PubMed  Google Scholar 

  • Zhang J, Qi J, Guo Y (2011b) Abnormal expression and clinical significance of HDGF and ADAM9 in non-small cell lung cancer. Zhongguo Yike Daxue Xuebao 40:280–281 (In Chinese)

    Google Scholar 

  • Zhang J, Qi J, Chen N, Guo Y, Fu W, Zhou B, He A (2011c) Highly expressed ADAM9 in completed resected stage I non-small cell lung cancer cases predicts a shortened survival. J Thorac Oncol 6:s1068–s1069

    Article  Google Scholar 

  • Zhang J, Chen N, Qi J (2013a) HDGF, ADAM9 involved in a novel pathway of cell growth and invasion of non-small cell lung cancer cells, may become novel molecular staging biomarkers, prognostic and predictive biomarkers of NSCLC. J Thorac Oncol 8:s753

    Article  Google Scholar 

  • Zhang J, Qi J, Chen N, Fu W, Zhou B, He A (2013b) High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer. Oncol Lett 5:1461–1466

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zhou Y, Zhou N, Fang W, Huo J (2010) Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol 5:58

    Article  PubMed Central  PubMed  Google Scholar 

  • Zhu CQ, Ding K, Strumpf F et al (2010) Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. JCO 28:4417–4424

    Article  CAS  Google Scholar 

  • Zubel A, Flechtenmacher C, Edler L, Alonso A (2009) Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix. Gynecol Oncol 114:332–336

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank C. Guan for technical assistance of immunohistochemistry staining, Dr. Y. Han and Dr. A. He for immunostaining evaluation and discussion. The authors appreciate Mr. Philip Whatley for copyediting the manuscript. This study was supported in part by IASLC/CRFA Prevention Fellowship, grants from The Education Department of Liaoning Province (No. 20060991) and from the Nature Science Foundation of Liaoning Province, China (No. 20102285), and Fund for Scientific Research of The First Hospital of China Medical University (No. FSFH1210).

Conflict of interest

The authors have no potential conflicts of interest.

Author information

Authors and Affiliations

  1. China Medical University Lung Cancer Center, The First Hospital of China Medical University, No. 155 North Nanjing Street, Heping District, Shenyang, 110001, People’s Republic of China

    Jun Zhang, Ning Chen, Juan Qi, Baosen Zhou & Xueshan Qiu

  2. Department of Logistic Management, College of Economics and Management, Liaoning University of Traditional Chinese Medicine, Shenyang, People’s Republic of China

    Ning Chen

  3. Department of Molecular Targeted Therapeutics, Cancer Institute, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    Jun Zhang & Juan Qi

  4. Department of Epidemics, China Medical University, Shenyang, People’s Republic of China

    Baosen Zhou

  5. Department of Pathology, China Medical University, Shenyang, People’s Republic of China

    Xueshan Qiu

Authors
  1. Jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ning Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Baosen Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xueshan Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Zhang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, J., Chen, N., Qi, J. et al. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer. J Cancer Res Clin Oncol 140, 1441–1449 (2014). https://doi.org/10.1007/s00432-014-1687-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1687-2

Keywords

Search

Navigation